30.04.2026 • Topics

Circular by Design

Seprify, founded by Lukas Schertel and Oliver Polcher, uses cellulose to create sustainable alternatives to TiO₂. The Cambridge spinout’s platform is backed by CTO Wadood Hamad’s expertise.

Interview with Lukas Schertel, Seprify

Photo
Lukas Schertel, Co-founder and CEO, Seprify
© Seprify

Co-founded by physicist Lukas Schertel and serial entrepreneur Oliver Polcher, Seprify transforms cellulose into high-performance functional ingredients inspired by nature’s light-scattering systems. Originating from research at the University of Cambridge, the Swiss start-up has developed a platform technology that enables sustainable alternatives to conventional ingredients such as titanium dioxide (TiO2). The leadership team is complemented by Chief Technology Officer Wadood Hamad, who brings extensive expertise in cellulose applications and processing.

CHEManager: Can you explain the core innovation in simple terms for our readers?

Lukas Schertel: Seprify engineers cellulose, the most abundant natural polymer, into microstructured particles that control how light interacts with a material. Instead of relying on chemical composition, we design the structure of cellulose at the micro-scale to achieve properties like whiteness, opacity, or SPF boosting.

Nature does this extremely well. For example, the Cyphochilus beetle (a core inspiration for our technology) appears intensely white not because of pigments, but because of how its microscopic structure scatters light. We replicate that same principle using cellulose. The result is a single, bio-based material that can deliver multiple functions across a range of industries from personal care and cosmetics to food, pet food, nutraceuticals and coatings.

Continue with login

No account yet?

Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.

Register

Company

Logo:

Seprify

Route de l’Ancienne Papeterie 180
1723 Marly
Switzerland

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

most read